Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2 - PubMed (original) (raw)

Comparative Study

. 1995 Oct 15;165(2):289-93.

doi: 10.1006/cimm.1995.1216.

Affiliations

• PMID: 7553894
• DOI: 10.1006/cimm.1995.1216

Comparative Study

Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2

W Munger et al. Cell Immunol. 1995.

Abstract

Interleukin-15 is a new cytokine that stimulates the proliferation of T cells and other cells of the immune system. Some of the biological properties of interleukin-15 overlap that of interleukin-2. Using murine models, the present studies have shown that interleukin-15, in vivo, is three to four times more potent than interleukin-2 in generating cytolytic effector splenocytes that lyse YAC target cells. It is approximately one-third as potent as interleukin-2 in inducing specific cytolytic cells that lyse allogeneic target cells. Interleukin-15 is approximately half as potent as interleukin-2 in suppressing pulmonary metastasis induced by MCA-205 tumor cells. The dose of interleukin-15 required to induce pulmonary vascular leak in mice is six times higher than that required for interleukin-2. These results support the view that interleukin-15 exhibits a therapeutic index that is superior to interleukin-2.

PubMed Disclaimer

Similar articles

• Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
  Tanaka F, Hashimoto W, Okamura H, Robbins PD, Lotze MT, Tahara H. Tanaka F, et al. Cancer Res. 2000 Sep 1;60(17):4838-44. Cancer Res. 2000. PMID: 10987295
• Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
  Harada M, Matsuzaki G, Yoshikai Y, Kobayashi N, Kurosawa S, Takimoto H, Nomoto K. Harada M, et al. Cancer Res. 1993 Jan 1;53(1):106-11. Cancer Res. 1993. PMID: 8093229
• Interleukin-15 induces the expression of mRNAs of cytolytic mediators and augments cytotoxic activities in primary murine lymphocytes.
  Ye W, Young JD, Liu CC. Ye W, et al. Cell Immunol. 1996 Nov 25;174(1):54-62. doi: 10.1006/cimm.1996.0293. Cell Immunol. 1996. PMID: 8929454
• Antitumor activity of interleukin-12.
  Brunda MJ, Gately MK. Brunda MJ, et al. Clin Immunol Immunopathol. 1994 Jun;71(3):253-5. doi: 10.1006/clin.1994.1081. Clin Immunol Immunopathol. 1994. PMID: 7911077 Review. No abstract available.
• Interleukin 2 and cancer.
  Bubeník J, Símová J, Bubeníková D. Bubeník J, et al. Folia Biol (Praha). 1992;38(3-4):155-69. Folia Biol (Praha). 1992. PMID: 1426413 Review. No abstract available.

Cited by

• Computational modeling study of IL-15-NGR peptide fusion protein: a targeted therapeutics for hepatocellular carcinoma.
  Fatima T, Mubasher MM, Rehman HM, Niyazi S, Alanzi AR, Kalsoom M, Khalid S, Bashir H. Fatima T, et al. AMB Express. 2024 Aug 7;14(1):91. doi: 10.1186/s13568-024-01747-8. AMB Express. 2024. PMID: 39133343 Free PMC article.
• Cytokine Gene Vaccine Therapy for Treatment of a Brain Tumor.
  Lichtor T, Tang B, Roy EJ. Lichtor T, et al. Brain Sci. 2023 Oct 25;13(11):1505. doi: 10.3390/brainsci13111505. Brain Sci. 2023. PMID: 38002466 Free PMC article. Review.
• IL-15 Priming Alters IFN-γ Regulation in Murine NK Cells.
  Cimpean M, Keppel MP, Gainullina A, Fan C, Sohn H, Schedler NC, Swain A, Kolicheski A, Shapiro H, Young HA, Wang T, Artyomov MN, Cooper MA. Cimpean M, et al. J Immunol. 2023 Nov 15;211(10):1481-1493. doi: 10.4049/jimmunol.2300283. J Immunol. 2023. PMID: 37747317 Free PMC article.
• Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC.
  Stravokefalou V, Stellas D, Karaliota S, Nagy BA, Valentin A, Bergamaschi C, Dimas K, Pavlakis GN. Stravokefalou V, et al. Front Immunol. 2023 Jan 13;13:1014802. doi: 10.3389/fimmu.2022.1014802. eCollection 2022. Front Immunol. 2023. PMID: 36713398 Free PMC article.
• Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors.
  Conlon K, Watson DC, Waldmann TA, Valentin A, Bergamaschi C, Felber BK, Peer CJ, Figg WD, Potter EL, Roederer M, McNeel DG, Thompson JA, Gupta S, Leidner R, Wang-Gillam A, Parikh NS, Long D, Kurtulus S, Ho Lee L, Chowdhury NR, Bender F, Pavlakis GN. Conlon K, et al. J Immunother Cancer. 2021 Nov;9(11):e003388. doi: 10.1136/jitc-2021-003388. J Immunother Cancer. 2021. PMID: 34799399 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • Mouse Genome Informatics (MGI)